Public Policy Dynamics Germany #2
Health and Politics in Germany
|Total COVID-19 cases:||2,192,850|
|14-day total COVID-19 cases per 100,000:||188|
|Total COVID-19 deaths:||55,752|
- Chancellor Angela Merkel (Christian Democratic Union, CDU) and the chairpersons of the Conference of State Ministers have agreed to discuss Germany’s and the EU’s struggling vaccination campaigns on 1 February at 2 pm.
- According to figures from the Robert Koch Institute (RKI), the 7-day viral incidence is below the threshold of 100 for the first time since the end of October. This means that the number of new infections reported within 7 days has roughly halved since the peak just before Christmas. The 7-day incidence was 197.6 on 22 December. The policy target is a 7-day incidence of less than 50.
- The German Government has commissioned 200,000 doses of new Covid-19 drugs. The active substance based on monoclonal antibodies can mitigate severe courses of COVID-19 in high-risk patients in individual cases. "They act like a passive vaccination", the Federal Minister of Health, Jens Spahn (Christian Democratic Union, CDU), affirmed.
- Amid growing tensions between Member States, the European Commission and vaccine manufacturers, Chancellor Angela Merkel (Christian Democratic Union, CDU) and the chairpersons of the Conference of State Ministers Are to hold a critical discussion on vaccines on 1 February.
- In addition to members of the Federal Government and the heads of government of the Länder, representatives of the vaccine manufacturers and the associations concerned will also take part in this discussion to iron out concerns that have mounted over the past weeks over vaccine supply.
- Health Minister Jens Spahn (Christian Democratic Union, CDU), has stressed that uniform and reliable action is necessary to foster trust within the German and EU populations. Spahn thus suggested there is an "obvious need for coordination" between the Länder, the federal government and the European Commission.
- The Federal Government has commissioned 200,000 doses of new COVID-19 drugs for Germany. The active substance, based on monoclonal antibodies, can protect against severe prognoses of Covid-19 in high-risk patients. Jens Spahn affirmed “they act like a passive vaccination”. According to the Federal Ministry of Health, the antibodies will be applied after an individual risk-benefit assessment has been conducted by the treating doctors.
- Monoclonal antibodies are intended to disable the virus after an infection. Monoclonal means that the antibodies used are all the same and attack the virus at a firmly defined target. “According to available studies, the medication could possibly help to limit the amount of virus in the body and thus have a positive influence on the course of the disease,” a ministry spokeswoman informed.
- According to figures from the Robert Koch Institute (RKI), the 7-day incidence is below the threshold of 100 for the first time since the end of October. This means that the number of new infections reported within 7 days has roughly halved since the peak just before Christmas – on 22 December, the 7-day incidence was 197.6. The policy target is a 7-day incidence of less than 50.
- The RKI counts 2,178,828 proven infections with SARS-CoV-2 in Germany since the beginning of the pandemic (as of 28 January 2020, 00.00 hrs). The actual total number is likely to be much higher, as many infections go undetected. The total number of people who have died from or with the involvement of a confirmed infection with SARS-CoV-2 rose to 54,913.